Chemotherapy-Induced Anemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia), By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

Global Chemotherapy-Induced Anemia Market was valued at USD 2.86 Billion in 2024 and is expected to reach USD 4.31 Billion by 2030 with a CAGR of 7.02% during the forecast period. The Global Chemotherapy-Induced Anemia Market has become a significant concern in the field of oncology. As chemotherapy continues to be a primary treatment option for cancer patients, the prevalence of chemotherapy-induced anemia (CIA) has also risen. This condition not only affects the quality of life for cancer patients but also presents a substantial market for pharmaceutical companies and healthcare providers. Chemotherapy-induced anemia is a common side effect of chemotherapy treatment for cancer. It occurs when chemotherapy drugs suppress the bone marrow's ability to produce red blood cells, leading to a decrease in hemoglobin levels in the blood. This condition can result in fatigue, weakness, shortness of breath, and a reduced ability to tolerate cancer treatment. Managing CIA has become a critical aspect of cancer care, and as a result, the demand for effective treatments has grown. CIA is a widespread issue affecting cancer patients. According to the American Cancer Society, around 30-90% of cancer patients receiving chemotherapy experience some degree of anemia. The market for CIA management includes erythropoiesis-stimulating agents (ESAs), iron supplements, blood transfusions, and novel therapies. ESAs, such as erythropoietin-stimulating agents and darbepoetin alfa, have been commonly used to manage CIA, but safety concerns and regulatory changes have impacted their usage. Pharmaceutical companies such as Amgen, Johnson & Johnson, and Roche are among the key players in the CIA market, developing and marketing drugs to address this condition. The Global Chemotherapy-Induced Anemia Market is a dynamic landscape with its share of challenges and opportunities. While regulatory concerns and reimbursement issues pose hurdles, ongoing research, patient-centered care, collaboration, and market expansion provide a promising outlook. As the healthcare industry continues to prioritize the well-being of cancer patients, advancements in CIA management will play a crucial role in enhancing the quality of life for those undergoing chemotherapy treatment. Pharmaceutical companies and healthcare providers must stay vigilant and innovative in addressing the needs of this growing patient population.

Key Market Drivers

Rising Incidence of Cancer is Driving the Global Chemotherapy-Induced Anemia Market

Cancer continues to be a major global health concern, affecting millions of lives each year. As the incidence of cancer rises worldwide, so does the demand for effective cancer treatments, including chemotherapy. While chemotherapy has been instrumental in battling cancer, it is not without its side effects. One such side effect that is garnering increasing attention is chemotherapy-induced anemia. The rising incidence of cancer is driving the global chemotherapy-induced anemia market, prompting research, innovation, and the development of therapies to address this pressing concern. Cancer is a formidable global health challenge. According to World Cancer Research Fund, in 2022, there were a total of 19,976,499 cancer cases globally, including non-melanoma skin cancer (NMSC). When NMSC is excluded, the number of cancer cases worldwide was 18,741,966. Among these, 9,566,825 cases were in men and 9,175,141 in women.

These numbers are expected to increase substantially in the coming years due to factors such as an aging population, lifestyle changes, and improved cancer detection methods. The rising incidence of cancer is a driving force behind the increasing prevalence of chemotherapy-induced anemia. Chemotherapy-induced anemia has a significant impact on the quality of life for cancer patients. It can lead to reduced physical activity, increased fatigue, cognitive impairment, and a decreased ability to tolerate chemotherapy treatment. These symptoms can make it difficult for patients to carry out their daily activities, work, or engage in social interactions, ultimately affecting their overall well-being.

Recognizing the detrimental effects of chemotherapy-induced anemia on cancer patients, the global healthcare industry has been actively addressing this issue. This has led to the emergence of the chemotherapy-induced anemia market, which focuses on developing therapies and treatments to manage anemia in cancer patients undergoing chemotherapy. Erythropoiesis-Stimulating Agents (ESAs) are medications that stimulate the production of red blood cells in the bone marrow. They are often used to treat chemotherapy-induced anemia and have been a significant part of the market. Iron deficiency is a common cause of anemia. Iron supplements can help replenish iron stores and improve red blood cell production. In severe cases of chemotherapy-induced anemia, blood transfusions may be necessary to boost hemoglobin levels and improve oxygen delivery to tissues. Ongoing research and development efforts are leading to the emergence of innovative therapies such as erythropoietin receptor agonists and novel iron formulations, which hold promise for more targeted and effective treatment of chemotherapy-induced anemia.

Government Support and Reimbursement Policies

Government support and favorable reimbursement policies have significantly influenced the global chemotherapy-induced anemia market. In many countries, the government has been actively involved in ensuring access to essential cancer treatments, including those aimed at managing chemotherapy-induced anemia. Reimbursement policies for chemotherapy-induced anemia therapies vary across countries, but many governments have recognized the importance of managing this condition as part of comprehensive cancer care. In the United States, for example, Medicare and private health insurers provide coverage for several treatment options for CIA, including ESAs, iron therapy, and blood transfusions. This ensures that a broad range of patients have access to effective treatment for anemia, particularly those undergoing chemotherapy. Similarly, in European countries, national health systems or insurance schemes typically cover therapies that alleviate CIA symptoms, allowing patients to access these medications at an affordable cost. Government support in the form of funding for cancer research has also accelerated the development of new and more effective treatments for chemotherapy-induced anemia. Additionally, the approval of new drugs and biologics by regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA), further facilitates market growth. Reimbursement for chemotherapy-induced anemia treatments is also a key factor that enables pharmaceutical companies to expand their offerings in this space. By ensuring that patients can afford the medications they need, governments have increased the demand for therapies that address CIA, contributing to market expansion. As more treatment options for CIA become available, there is a continued focus on ensuring equitable access to these therapies through favorable policies. This further enhances the growth of the global chemotherapy-induced anemia market by promoting early diagnosis and treatment, improving patient outcomes, and reducing the economic burden associated with the condition.

Growing Focus on Personalized Medicine in Cancer Treatment

The growing focus on personalized medicine in cancer treatment has played a significant role in driving the global chemotherapy-induced anemia market. As cancer treatment becomes more targeted, physicians are increasingly using genomic and molecular profiling to customize therapy plans based on individual patient characteristics, such as genetic makeup and tumor-specific markers. This personalized approach not only improves the effectiveness of cancer treatments but also helps reduce the side effects associated with chemotherapy, including anemia. In personalized medicine, healthcare providers aim to select therapies that are tailored to the patient’s specific genetic and molecular profile, optimizing treatment regimens to minimize adverse effects. For patients undergoing chemotherapy, personalized treatment strategies often include selecting chemotherapeutic agents and dosages that reduce the likelihood of severe anemia, thus reducing the need for treatment with blood transfusions or erythropoiesis-stimulating agents (ESAs). This more personalized approach to chemotherapy is contributing to better outcomes for cancer patients, including improved management of chemotherapy-induced anemia. As the trend toward personalized medicine grows, it is expected that more effective and targeted therapies will be developed to address chemotherapy-induced anemia, further expanding the market. In addition, the increased use of precision oncology tools, such as next-generation sequencing and biomarker analysis, has made it easier for healthcare providers to predict which patients are at higher risk of developing CIA and intervene earlier to prevent severe anemia. As a result, personalized medicine is enabling more proactive management of chemotherapy-induced anemia, improving patient quality of life, and driving the demand for specialized treatments. This shift towards more individualized care in cancer treatment is expected to continue influencing the global chemotherapy-induced anemia market as the industry embraces a more tailored and patient-centered approach to therapy.

Increasing Geriatric Population is Driving the Global Chemotherapy-Induced Anemia Market

The world is witnessing a significant demographic shift, with the aging population growing at an unprecedented rate. As people live longer and cancer treatment becomes more prevalent, a concerning side effect of chemotherapy-induced anemia is emerging as a critical healthcare challenge. Chemotherapy-induced anemia is a condition characterized by a decrease in red blood cell count due to cancer treatment. This condition can lead to severe fatigue, reduced quality of life, and even treatment interruptions. As the aging population continues to rise, so does the demand for effective anemia management, which is driving the global chemotherapy-induced anemia market. The aging population is a significant driver of the global chemotherapy-induced anemia market. According to WHO, by 2050, it is projected that 80% of the global elderly population will reside in low- and middle-income countries. The rate of population aging is accelerating compared to previous decades. In 2020, the number of individuals aged 60 and above surpassed the number of children under 5 years of age. From 2015 to 2050, the percentage of the global population aged over 60 is expected to nearly double, increasing from 12% to 22%.

As people age, they become more susceptible to cancer and its associated treatments. Older individuals often have weaker immune systems and may require more aggressive cancer treatment, including chemotherapy. This demographic shift towards an older population is a double-edged sword, as it both increases the incidence of cancer and the likelihood of chemotherapy-induced anemia. Additionally, older individuals often have multiple comorbidities, making them more vulnerable to the adverse effects of anemia. These factors combine to create a growing demand for effective anemia management among the aging population. Several factors contribute to the growth of the global chemotherapy-induced anemia market. Cancer rates continue to rise globally, with aging being a significant risk factor. As more people undergo chemotherapy, the incidence of chemotherapy-induced anemia also increases. Pharmaceutical companies are investing in research and development to create better treatments for chemotherapy-induced anemia. New medications and therapies are emerging, offering improved management options for patients. Increasing awareness among healthcare professionals about the importance of early detection and management of chemotherapy-induced anemia is driving the demand for appropriate treatments. Healthcare providers are increasingly recognizing the importance of comprehensive supportive care for cancer patients. Anemia management is a critical component of such care, further fueling market growth. The emphasis on patient-centered care has led to a greater focus on improving the quality of life for cancer patients. Managing anemia effectively can significantly enhance a patient's well-being during cancer treatment.

Download Free Sample Report

Key Market Challenges

Regulatory Barriers

Regulatory barriers pose significant challenges for companies in the CIA (Cellular Immunotherapy and Advanced Biologicals) market. Navigating the complex and ever-changing regulatory landscape is a cumbersome and resource-intensive process for pharmaceutical and biotech firms. Regulatory agencies such as the FDA, EMA, and others across the globe require comprehensive preclinical and clinical data to assess the safety, efficacy, and quality of new therapies and biologics before granting approval. Clinical trials are often long and costly, extending the time to market and making it challenging for companies to recoup their investments quickly. Furthermore, the regulatory requirements can differ significantly across regions, adding complexity for companies operating internationally. Firms must carefully tailor their clinical trial designs and data reporting to meet the specific demands of each regulatory body, which can increase the likelihood of delays and failures. In addition, some regions may lack clear guidance or have slower approval timelines, complicating the ability to expand and commercialize products globally. Given the high cost of compliance and regulatory delays, companies often find themselves facing financial strain, making it difficult for smaller firms or startups to compete with established players who have deeper resources and experience navigating the regulatory maze.

Market Competition

The CIA market is characterized by intense competition, making it a challenging space for both established and emerging players. With advancements in cellular immunotherapies, gene therapies, and biologics, multiple pharmaceutical and biotechnology companies are racing to develop innovative therapies for conditions like cancer, autoimmune diseases, and other chronic conditions. While this heightened competition drives progress and innovation, it also presents challenges for new entrants. Established companies, especially those with a broad product portfolio and a well-established market presence, hold a significant competitive advantage. Their ability to leverage vast financial resources, research infrastructure, and regulatory expertise allows them to dominate the market and bring products to market more efficiently. These established players can also afford large-scale manufacturing capabilities and distribution networks, enabling them to maintain a strong foothold across regions. As a result, newer companies often find it difficult to compete, struggling with limited resources and facing significant barriers to entry. To overcome these challenges, smaller firms need to differentiate their products, forge strategic partnerships, and innovate to meet niche market needs. However, even with these strategies, the intense competition in the CIA market means that survival often depends on the ability to quickly deliver safe and effective therapies, which is a formidable challenge in a rapidly evolving field. Moreover, the pressure to innovate, combined with rising research and development costs, makes it difficult for new players to secure funding and resources to successfully bring their products to market. Thus, although the CIA market offers significant potential, competition remains a critical hurdle for market participants to navigate.

Key Market Trends

Rising Awareness and Early Diagnosis of Chemotherapy-Induced Anemia

A key driver of the global chemotherapy-induced anemia (CIA) market is the increasing awareness and early diagnosis of the condition. As the global cancer incidence rises and treatment regimens become more complex, there has been a growing recognition of the impact of chemotherapy-induced anemia on patients' quality of life. Chemotherapy-induced anemia is a common side effect that can significantly affect the patient's ability to undergo treatment and recover from cancer therapy. Historically, anemia in cancer patients was often underdiagnosed or underappreciated, but as healthcare professionals become more educated about the condition and its detrimental effects, the demand for treatment options has grown.  

In February 2023, the U.S. Food and Drug Administration approved Jesduvroq tablets (daprodustat) as the first oral treatment for anemia (decreased number of red blood cells) caused by chronic kidney disease for adults who have been receiving dialysis for at least four months. Jesduvroq is not approved for patients who are not on dialysis. Other FDA-approved treatments for this condition are injected into the blood or under the skin. 

Additionally, early detection through improved diagnostic methods, such as blood tests, has allowed healthcare providers to identify anemia in the initial stages of chemotherapy. This has paved the way for more effective intervention strategies, including the use of erythropoiesis-stimulating agents (ESAs), iron supplements, and blood transfusions. With greater awareness of the adverse effects of anemia, physicians are more likely to adopt a proactive approach to managing CIA, which has spurred market growth. Furthermore, the development of guidelines and treatment protocols focused on managing chemotherapy-induced anemia has contributed to a standardized and well-organized approach, which has led to an increase in patient screenings and more comprehensive management of CIA. As a result, patients are now able to receive timely treatment to address anemia, thereby enhancing their response to chemotherapy and improving their overall treatment outcomes. The rising awareness about CIA also extends to patient advocacy groups, which play a significant role in educating cancer patients about anemia and pushing for better treatment options. This advocacy, combined with growing awareness among healthcare professionals, has led to increased demand for medications and therapies that target CIA, thereby driving the global market for chemotherapy-induced anemia treatments.

Technological Advancements

In recent years, the healthcare industry has witnessed remarkable advancements in technology, reshaping the landscape of patient care and treatment outcomes. One area that has seen significant progress is the management of chemotherapy-induced anemia (CIA), a common side effect of cancer treatment. With technological innovations and breakthroughs in the pharmaceutical sector, the global chemotherapy-induced anemia market is on the rise, offering hope to cancer patients grappling with this debilitating condition. In May 2023, FibroGen, Inc. and its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd., have announced positive topline results from their Phase 3 clinical trial of roxadustat for the treatment of anemia in patients undergoing chemotherapy for non-myeloid malignancies in China. Roxadustat showed non-inferiority to recombinant erythropoietin alfa (SEPO®) based on the primary endpoint, which was the change in hemoglobin (Hb) levels from baseline to the average level during weeks 9-13. The preliminary safety analysis revealed that the adverse event profile of roxadustat was generally consistent with prior findings, supporting a favorable benefit-risk profile for this patient group.

Advances in drug formulation technologies have led to the creation of erythropoiesis-stimulating agents (ESAs), which stimulate the production of red blood cells. Newer ESAs are more effective, have fewer side effects, and offer more convenient dosing options for patients. Precision medicine and targeted therapies are transforming cancer treatment. These therapies aim to reduce the toxic effects of chemotherapy on healthy cells, including those responsible for red blood cell production. Targeted therapies help mitigate anemia while enhancing the effectiveness of cancer treatment. The development and approval of biosimilars, which are highly similar to existing biologic drugs, have increased access to effective anemia treatments at more affordable prices. Biosimilars are the result of advancements in biotechnology and regulatory pathways. The advent of genomics and personalized medicine has allowed healthcare providers to tailor treatment plans to individual patients. This approach helps identify patients at higher risk of developing chemotherapy-induced anemia and enables proactive interventions to manage their condition. Technology has facilitated remote monitoring of patients, allowing healthcare providers to track anemia symptoms and adjust treatment plans in real-time. This has improved patient outcomes and reduced hospital visits, especially during the ongoing COVID-19 pandemic.

The combination of these technological advancements has significantly expanded the chemotherapy-induced anemia market. The global market is expected to continue its upward trajectory, providing substantial opportunities for pharmaceutical companies, biotech firms, and healthcare providers. Moreover, the demand for these advanced treatments is expected to surge as cancer incidence rates continue to rise worldwide. Additionally, the increasing focus on patient-centric care and the adoption of value-based healthcare models are driving the development of innovative anemia management solutions. As a result, there is a growing emphasis on providing holistic care to cancer patients, addressing not only the cancer itself but also its side effects, such as anemia.

Segmental Insights

Treatment Type Insights

Based on the category of Treatment Type, Erythropoiesis-stimulating agents (ESAs) emerged as the dominant player in the global market for Chemotherapy-Induced Anemia. ESAs are a class of pharmaceuticals that stimulate the production of red blood cells in the bone marrow. They work by mimicking the action of erythropoietin, a hormone produced by the kidneys that plays a pivotal role in regulating red blood cell production. ESAs like epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) can be administered via injection to bolster the patient's red blood cell count and alleviate the symptoms of anemia. Numerous clinical studies and real-world evidence have demonstrated the effectiveness of ESAs in managing CIA. Patients receiving ESAs often experience a significant improvement in their hemoglobin levels, resulting in reduced fatigue and an overall enhanced quality of life. ESAs are typically administered through subcutaneous injections, making them relatively convenient for both patients and healthcare providers compared to other treatment options, such as blood transfusions. While ESAs may require initial investments, they often prove cost-effective in the long run. Fewer blood transfusions are needed, which can be both expensive and associated with potential risks. By addressing anemia-related fatigue and weakness, ESAs can help patients stay on their prescribed chemotherapy regimens, potentially leading to better treatment outcomes. ESAs are increasingly being explored for their potential in other areas beyond CIA, such as managing anemia in patients with chronic kidney disease, further expanding their market reach.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the global Chemotherapy-Induced Anemia market, holding the largest market share in terms of value. North America boasts a highly developed healthcare infrastructure, making it a natural hub for cutting-edge cancer treatments and supportive care. The region is home to renowned cancer centers and hospitals equipped with state-of-the-art facilities for both cancer treatment and research. This infrastructure allows for early diagnosis and comprehensive management of chemotherapy-induced anemia. North America's dominance in the global CIA market is largely attributable to its robust research and innovation ecosystem. The region invests heavily in cancer research, leading to the development of novel treatments and therapies aimed at mitigating anemia in cancer patients. Pharmaceutical companies and research institutions collaborate closely to create more effective and targeted interventions for CIA.

Recent Developments

• In December 2024, AnemiaPhone, a technology developed by a multidisciplinary team of researchers at Cornell, has been transferred to the Indian Council of Medical Research (ICMR) under the government of India for integration into its anemia, women’s health, and maternal and child health programs nationwide. This innovative tool will facilitate rapid and cost-effective screening and diagnosis of iron deficiency at the point of care across India. Iron deficiency, the leading cause of anemia, affects one in four people and impairs the body’s ability to produce enough healthy red blood cells to carry oxygen. AnemiaPhone will play a crucial role in addressing this widespread health issue across the country.
• In March 2024, Pharmaceutical manufacturer Akums announced on Saturday the launch of India’s first indigenous hydroxyurea oral solution, designed for the treatment of sickle cell disease in children.
• In March 2024, Akebia Therapeutics announced its plans to launch its anemia drug, Vafseo, to the dialysis community. Company officials also revealed their intention to collaborate with the FDA for further testing of the drug for the pre-dialysis market. In March, Akebia received approval for vadadustat (Vafseo) to treat anemia in dialysis patients. However, the FDA rejected Akebia's 2022 application to extend the drug's use to non-dialysis patients, citing an increased risk of major adverse cardiovascular events (MACE) compared to erythropoiesis-stimulating agents (ESAs).
• In February 2024, Emcure Pharmaceuticals launched the 'Unmask Anemia' initiative to raise awareness about iron deficiency anemia in India. The initiative is focused on increasing awareness, improving detection, and enhancing the treatment of iron deficiency anemia, particularly among women across the country.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Panacea Biotec Limited
• SBI Pharmaceuticals Co., Ltd
• Sumitomo Dainippon Pharma Co., Ltd.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.
• Amgen Inc.
• Astellas Pharma Inc.

Report Scope:

In this report, the Global Chemotherapy-Induced Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chemotherapy-Induced Anemia Market, By Disease Type:

o   Mild Anemia

o   Moderate Anemia

o   Severe Anemia

• Chemotherapy-Induced Anemia Market, By Treatment Type :

o   RBC Transfusions

o   Erythropoiesis-stimulating agents (ESAs)

o   Iron Supplementation

• Chemotherapy-Induced Anemia Market, By Drug Type:

o   Epogen Injection

o   Procrit Injection

o   Androxy Oral

o   Aranesp injection

o   Epoetin Alfa Injection

o   Others

• Chemotherapy-Induced Anemia Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Chemotherapy-Induced Anemia Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Chemotherapy-Induced Anemia Market.

Available Customizations:

Global Chemotherapy-Induced Anemia market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).